A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
Public ClinicalTrials.gov record NCT07464314. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Observer-Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of an Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This early-stage study will look at a new mRNA vaccine that combines defenses against both seasonal flu and COVID-19 in terms of its safety and how it builds protection. Healthy adults aged 65 to 85 will receive different doses of this new vaccine, a standard flu vaccine, or COVID-19 vaccine. The study will assess any side effects or health issues, and additional blood samples will be collected at specific times to evaluate how well participants bodies build protection against the flu and COVID-19.
Study identification
- NCT ID
- NCT07464314
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 225 participants
Conditions and interventions
Conditions
Interventions
- Investigational mRNA Seasonal Flu/COVID-19 Combination (Flu/COVm) Vaccine Biological
- Licensed Seasonal Influenza Vaccine Biological
- Licensed COVID-19 Vaccine Biological
Biological
Eligibility (public fields only)
- Age range
- 65 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 8, 2026
- Primary completion
- Dec 2, 2026
- Completion
- Jun 2, 2027
- Last update posted
- Jun 29, 2026
2026 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Anniston | Alabama | 36207 | Recruiting |
| GSK Investigational Site | Little Rock | Arkansas | 72204 | Recruiting |
| GSK Investigational Site | Fair Oaks | California | 95628 | Recruiting |
| GSK Investigational Site | San Diego | California | 92123 | Recruiting |
| GSK Investigational Site | Miami | Florida | 33186 | Recruiting |
| GSK Investigational Site | Miami Lakes | Florida | 33016 | Recruiting |
| GSK Investigational Site | West Palm Beach | Florida | 33409 | Recruiting |
| GSK Investigational Site | Stockbridge | Georgia | 30281 | Recruiting |
| GSK Investigational Site | Austin | Texas | 78705 | Recruiting |
| GSK Investigational Site | Charlottesville | Virginia | 22911 | Recruiting |
| GSK Investigational Site | Newport News | Virginia | 23606 | Recruiting |
| GSK Investigational Site | Seattle | Washington | 98104 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07464314, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 29, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07464314 live on ClinicalTrials.gov.